These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 21622594

  • 1. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA.
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [Abstract] [Full Text] [Related]

  • 2. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA.
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [Abstract] [Full Text] [Related]

  • 3. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH, Kim W, Li XF, Jung IJ, Kim HJ.
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [Abstract] [Full Text] [Related]

  • 4. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ.
    JAMA Neurol; 2013 Sep 01; 70(9):1110-7. PubMed ID: 23897062
    [Abstract] [Full Text] [Related]

  • 5. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
    Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R.
    JAMA Neurol; 2013 Mar 01; 70(3):394-7. PubMed ID: 23358868
    [Abstract] [Full Text] [Related]

  • 6. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME, Andreadou E, Koutsis G, Koutoulidis V, Anagnostouli M, Katsika P, Evangelopoulos DS, Evdokimidis I, Kilidireas C.
    J Neurol Sci; 2017 Jan 15; 372():92-96. PubMed ID: 28017256
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T.
    Neurology; 2011 Apr 12; 76(15):1310-5. PubMed ID: 21482945
    [Abstract] [Full Text] [Related]

  • 9. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A.
    Neurology; 2011 Aug 16; 77(7):659-66. PubMed ID: 21813788
    [Abstract] [Full Text] [Related]

  • 10. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
    Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T.
    Mult Scler; 2009 Aug 16; 15(8):1006-8. PubMed ID: 19667025
    [Abstract] [Full Text] [Related]

  • 11. Failure of natalizumab to prevent relapses in neuromyelitis optica.
    Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O, Neuromyelitis Optica Study Group.
    Arch Neurol; 2012 Feb 16; 69(2):239-45. PubMed ID: 22332191
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of rituximab treatment for neuromyelitis optica.
    Fernández-Megía MJ, Casanova-Estruch B, Pérez-Miralles F, Ruiz-Ramos J, Alcalá-Vicente C, Poveda-Andrés JL.
    Neurologia; 2015 Oct 16; 30(8):461-4. PubMed ID: 25444411
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W.
    Brain; 2008 Nov 16; 131(Pt 11):3072-80. PubMed ID: 18945724
    [Abstract] [Full Text] [Related]

  • 19. Rituximab use in pediatric central demyelinating disease.
    Beres SJ, Graves J, Waubant E.
    Pediatr Neurol; 2014 Jul 16; 51(1):114-8. PubMed ID: 24768216
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of rituximab in pediatric neuromyelitis optica.
    Mahmood NA, Silver K, Onel K, Ko M, Javed A.
    J Child Neurol; 2011 Feb 16; 26(2):244-7. PubMed ID: 21183724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.